SWTXSpringWorks Therapeutics Inc

$0.00
$0.00
(0.00%)
Today
Updated:
Reported EarningsJul 30
Mkt Cap$3.54B
Vol5.01M
55

Bullish Sentiment

How do you feel about SWTX?

News
all
press releases
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
Zacks
News Placeholder
More News
News Placeholder
SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout
After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.
Stocktwits
News Placeholder
SpringWorks Therapeutics springs higher as Merck KGaA takeover said close
Investing.com -- Shares of SpringWorks Therapeutics Inc (NASDAQ:SWTX) surged higher Thursday afternoon on reports that a potential takeover of the company by Germany’s Merck KGaA (ETR:MRCG) is getting close.
investing.com
News Placeholder
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week
Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.
Stocktwits
News Placeholder
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?
Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.
Stocktwits
News Placeholder
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect
Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.
Stocktwits
News Placeholder
Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets
Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.
Stocktwits
News Placeholder
Springworks surges as Germany's Merck KGaA said to be targeting takeover
Investing.com -- Shares of Springworks Therapeutics (NASDAQ:SWTX) surged over 37% on Monday following reports that Germany’s Merck (NSE:PROR) KGaA is in advanced talks to acquire the U.S. biotech company, according to Reuters.
investing.com
<
...
1
>

Advertisement|Remove ads.